Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2022-10-07 00:00:00 ET · period of report 2022-10-06 · accession 0001562180-22-007124 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-10-07 | 2022-10-06 | SNDX | Metzger Michael A | CEO, Dir | S - Sale+OE | $25.29 | -16.2K | 17.7K | -48% | -$410.5K |
| D | 2022-10-07 | 2022-10-06 | SNDX | Metzger Michael A | CEO, Dir | M - OptEx | $8.77 | +16.2K | 33.9K | +92% | +$142.3K |
| D | 2022-10-07 | 2022-10-06 | SNDX | Metzger Michael A | CEO, Dir | M - OptEx | $0.00 | -16.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-10-06 | S | D | 16,231 | $25.29 | 17,659 | D | — | — | (F2) The sale prices ranged from $25.1500 to $25.4350. |
| 2 | Common | Common Stock | 2022-10-06 | M | A | 16,231 | $8.77 | 33,890 | D | — | — | |
| 3 | Derivative | Stock Options (Right to buy) | 2022-10-06 | M | D | 16,231 | $0.00 | 0 | D | $8.77 · — to 2027-02-06 | 16,231 Common Stock | (F3) This option is fully vested. |